KD-496

N/A

Report date: 2022/10/20 20:01:22

Base Information

Drug NameKD-496
Drug Alias NameKD-496KD-496(4th)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CLDN18 +[4] 
TargetsClaudin-18 splice variant 2NKG2D ligands
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Kaidi Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking UniversityNanjing Kaidi Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A